GlassScriptPhysician profile
David S Wells-Roth
NPI 1366576845
$40,195.67
in general payments reported to CMS, 2019-2025
34 companies · $3,950 in 2025
The $3,950 reported for 2025 was more than what 78% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $52.50 · 2021: $484 · 2022: $1,378 · 2023: $1,133 · 2024: $33K · 2025: $3,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $29K · Consulting Fee: $5,399 · Food and Beverage: $3,637 · Travel and Lodging: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $28,718.46 |
| Consulting Fee | $5,398.50 |
| Food and Beverage | $3,637.43 |
| Travel and Lodging | $273.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgentec | $29,218.46 | 2022-2024 | Ion, Tilink |
| 4web, INC. | $4,851.53 | 2019-2024 | Spine Truss System |
| Expanding Innovations, INC. | $2,398.50 | 2025 | X-Pac |
| Ecential Robotics | $798.96 | 2025 | |
| Nevro Corp. | $517.79 | 2021-2024 | Senza |
| Augmedics INC. | $350.27 | 2024-2025 | Xvision |
| Boston Scientific Corporation | $259.60 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Providence Medical Technology, INC. | $246.64 | 2022-2024 | |
| Stryker Corporation | $225.01 | 2019-2024 | Cascadia Interbody System |
| Ulrich Medical USA, INC. | $191.20 | 2024-2025 | |
| Globus Medical, INC. | $120.55 | 2025 | Senza, Vyrsa V1 |
| Zimvie INC. | $117.93 | 2023 | |
| Collegium Pharmaceutical, INC. | $100.70 | 2022-2025 | Belbuca, Xtampza |
| Zimmer Biomet Holdings, INC. | $95.65 | 2021 | |
| Djo, LLC | $88.71 | 2024 | Cmf |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $82.34 | 2019 | |
| Medtronic, INC. | $79.00 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Smith+Nephew, INC. | $45.54 | 2023 | Pico |
| Choice Spine, LLC | $44.98 | 2025 | Thunderbolt Minimally Invasive Pedicle Screw Systems, Stratofuse, Blackhawk Cervical Spacer System |
| Abbott Laboratories | $35.80 | 2020-2021 | |
| Vertos Medical, INC. | $34.58 | 2022 | |
| Protega Pharmaceutials INC | $32.23 | 2023-2024 | Roxybond |
| Foundation Fusion Solutions, LLC | $31.50 | 2024 | |
| Relievant Medsystems, INC. | $29.42 | 2023 | Intracept |
| Ossdsign USA Incorporated | $28.31 | 2025 | Ossdsign Catalyst |
| Intrinsic Therapeutics | $25.32 | 2022 | |
| Nalu Medical, INC. | $20.70 | 2023 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $20.10 | 2023 | Evoke Scs |
| Janssen Pharmaceuticals, INC | $18.63 | 2024 | Spravato |
| Highridge Medical LLC | $18.53 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Ebi, LLC | $18.53 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $16.38 | 2025 | |
| Portola Pharmaceuticals, LLC | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,797.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wells-Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.